Details of the Drug Formulations

General Information of Drug (ID: DMLYGH4)

• Drug Name: MK-4827 Drug Info
• Synonyms: 1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 3	[1]
Breast cancer	2C60-2C65	Phase 2	[2]
Ewing sarcoma	2B52	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 24958200
  CAS Number: 1038915-60-4
  TTD ID: D00BMF
  INTEDE ID: DR1164
  ACDINA ID: D00471

Full List of Drug Formulations Containing This Drug

Niraparib 100 mg capsule

Company	Formulation ID	FDA Description
TESARO	F15383	Erythrosine sodium anhydrous; Lactose monohydrate; Fd&c blue no. 1; Fd&c yellow no. 5; Magnesium stearate; Titanium dioxide; Gelatin hydrolysate (porcine skin, mw 3000)

Niraparib Tosylate 100mg capsule

Company	Formulation ID	FDA Description
Glaxosmithkline	F23352	Magnesium Stearate; Lactose Monohydrate; Titanium Dioxide; Gelatin; Fd&C Blue 1; Fd&C Red 3; Fd&C Yellow 5; Gelatin; Shellac; Dehydrated Alcohol; Isopropyl Alcohol; Butyl Alcohol; Propylene Glycol; Purified Water; Strong Ammonia Solution; Potassium Hydroxide; Black Iron Oxide

References

• [1] ClinicalTrials.gov (NCT03602859) A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)